Compositions and methods for topically treating diseases
First Claim
Patent Images
1. A method of treating disease, comprising topical administration to a subject in need thereof a therapeutically effective amount of a pharmaceutical agent formulated in a liposomal preparation.
1 Assignment
0 Petitions
Accused Products
Abstract
Described herein are compositions and methods for treating disease. In one aspect, the compositions comprise an anti-neoplastic agent together with a liposome preparation. In another aspect, the compositions of the present invention are directed toward the treatment of cancer. In a particular aspect, the cancer target is Kaposi'"'"'s sarcoma. The compositions described herein can be topically applied to a subject'"'"'s integumentary system using liposomal technology.
-
Citations
18 Claims
-
1. A method of treating disease, comprising topical administration to a subject in need thereof a therapeutically effective amount of a pharmaceutical agent formulated in a liposomal preparation.
-
2. The method of claim 1, wherein said disease is a cancer.
-
3. The method of claim 2, wherein said cancer is Kaposi'"'"'s sarcoma.
-
4. The method of claim 1, wherein said pharmaceutical agent is selected from the group consisting of paclitaxel, 5-FU, 5-FUdR, methotrexate, ara-C, 6-mercaptopurine, 6-thioguanine, hydroxyurea, mechlorethamine, phenylalanine mustard, chlorambucil, ethylenimines, methyl melamines, carmustine, lomustine, streptozocin, Cisplatin, Carboplatin, dacarbazine, procarbazine, doxorubicin, daunorubicin, mitomycin C, plycamycin, cyclophosphamide, melphalan, chlorambucil, carmustine, thiotepa, busulfan, prednisone, prednisolone, triamcinolone, and derivatives thereof.
-
5. The method of claim 4, wherein said pharmaceutical agent is paclitaxel and derivatives thereof.
-
6. The method of claim 5, wherein said derivatives are selected from the group consisting of 7-deoxy-docetaxol, 7,8-cyclopropataxanes, N-substituted 2-azetidones, 6,7-epoxy paclitaxels, 6,7-modified paclitaxels, 10-desacetoxytaxol, 10-deacetyltaxol, phosphonooxy and carbonate derivatives of taxol, taxol 2′
- ,7-di(sodium 1,2-benzene-dicarboxylate, 10-desacetoxy-11,12-dihydrotaxol-10,12(18)-diene derivatives, 10-desacetoxytaxol, Protaxol (2′
-and/or 7-O-ester derivatives ), (2′
-and/or 7-O-carbonate derivatives), asymmetric synthesis of taxol side chain, fluoro taxols, 9-deoxotaxane, (13-acetyl-9-deoxobaccatine III, 9-deoxotaxol, 7-deoxy-9-deoxotal, 10-desacetoxy-7-deoxy-9-deoxotaxol, derivatives containing hydrogen or acetyl group and a hydroxy and tert-butoxycarbonylamino, sulfonated 2′
-acryloyltaxol and sulfonated 2′
-O-acyl acid taxol derivatives, succinyltaxol, 2′
-γ
-aminobutyryltaxol formate, 2′
-acetyl taxol, 7-acetyl taxol, 7-glycine carbamate taxol, 2′
-OH-7-PEG(5000) carbamate taxol, 2′
-benzoyl and 2′
,7-dibenzoyl taxol derivatives, other prodrugs (2′
-acetyltaxol;
2′
,7-diacetyltaxol;
2′
succinyltaxol;
2′
-(beta-alanyl)-taxol), 2′
γ
-amino-butyryltaxol formate, ethylene glycol derivatives of 2′
-succinyltaxol, 2′
-glutaryltaxol, 2′
-(N,N-dimethylglycyl) taxol, 2′
-(2-(N,N-dimethylamino)propionyl)taxol, 2′
orthocarboxy-benzoyl taxol;
2′
aliphatic carboxylic acid derivatives of taxol, Prodrugs {2′
(N,N-diethylamino-propionyl)taxol, 2′
(N,N-dimethyglycyl)taxol, 7(N,N-dimethyl-glycyl)taxol, 2′
,7-di-(N,N-dimethylglycyl)taxol, 7(N,N-diethylaminopropionyl)taxol, 2′
,7-di(N,N-diethyl-aminopropionyl)taxol, 2′
-(L-glycyl)taxol, 7-(L-glycyl)taxol, 2′
,7-di(L-glycyl)taxol, 2′
-(L-alanyl)taxol, 7-(L-alanyl)taxol, 2′
,7-di(L-alanyl)taxol, 2′
-(L-leucyl)taxol, 7-(L-leucyl) taxol, 2′
,7-di(L-leucyl)taxol, 2′
-(L-isoleucyl)taxol, 7-(L-isoleucyl)taxol, 2′
,7-di(L-iso-leucyl)taxol, 2′
-(L-valyl)taxol, 7-(L-valyl)taxol, 2′
7-di(L-valyl)taxol, 2′
-(L-phenylalanyl) taxol, 7-(L-phenylalany)taxol, 2′
,7-di(L-phenylalanyl)taxol, 2′
-(L-prolyl)taxol, 7-(L-prolyl)taxol, 2′
,7-di(L-prolyl)taxol, 2′
-(L-lysyl)taxol, 7-(L-lysyl)taxol, 2′
,7-di(L-lysyl)taxol, 2′
-(L-glutamyl) taxol, 7-(L-glutamyl)taxol, 2′
,7-di(L-glutamyl)taxol, 2′
-(L-arginyl)taxol, 7-(L-arginyl)taxol, 2′
,7-di(L-arginyl)taxol}, Taxol analogs with modified phenylisoserine side chains, taxotere, (N-debenzoyl-N-tert-(butoxycaronyl)-10-de-acetyltaxol, and taxanes.
- ,7-di(sodium 1,2-benzene-dicarboxylate, 10-desacetoxy-11,12-dihydrotaxol-10,12(18)-diene derivatives, 10-desacetoxytaxol, Protaxol (2′
-
7. The method of claim 1, wherein said liposomal preparation comprises a lipid bilayer.
-
8. The method of claim 1, wherein said liposomal preparation encapsulates said pharmaceutical agent.
-
9. The method of claim 8, wherein said encapsulation is within an aqueous layer of said liposomal preparation.
-
10. The method of claim 1, wherein said liposomal preparation is selected from the group consisting of an ULV, MLV and OLV.
-
11. The method of claim 10, wherein said liposomal preparation is an ULV.
-
12. The method of claim 10, wherein said liposomal preparation is an MLV.
-
13. The method of claim 10, wherein said liposomal preparation is OLV.
-
14. The method of claim 1, wherein said liposomal preparation is multivesicular.
-
15. The method of claim 1 further comprising one or more excipients.
-
16. The method of claim 15, wherein said excipients are selected from the group consisting of alcohols, glycols, isopropyl myristate, water, mixtures thereof, eineol, D-limonene (with or without water), ethylene glycol or propylene glycol, phosphatidyl glycerol, dioleoylphosphatidyl glycerol, Transcutolo, or terpinolene;
- mixtures of isopropyl myristate and 1-hexyl-2-pyrrolidone, N-dodecyl-2-piperidinone or 1-hexyl-2-pyrrolidone, and sodium lauryl sulfate.
-
17. The method of claim 1, wherein said liposomal preparation is a nonionic nansomal formulation.
-
18. A method of treating cancer, comprising topical administration to a subject in need thereof a therapeutically effective amount of a pharmaceutical agent formulation in a liposomal preparation.
Specification